The popularity of CBD products has exploded in the U.S. in recent years, with sales in the U.S. cannabis dispensary channel alone rising from $8.4 million in May 2016 to $56.9 million in May 2020. And hemp-derived CBD products, containing less than 0.3% THC, are increasingly available via general retail channels, though CBD ingestibles are still officially off limits for sale in general retail channels in the U.S. and most other jurisdictions.
The legal cannabis market has exploded in recent years, with sales in the U.S. reaching an estimated $12.4 billion in 2019, forecast to rise to $31 billion by 2024. The market for cannabidiol (CBD) has also grown rapidly, with U.S. sales totaling $2.6 billion in 2019, on track to reach $18 billion by 2024. While THC and CBD are the most widely known and marketed compounds found in Cannabis sativa, a few of the other 113 currently identified cannabinoids show potential for therapeutic and recreational applications and have attracted the attention of both researchers and those in the industry.